Coaching to Up H2O Intake Does Not Slow eGFR Decline in CKD

Share this content:
Coaching to Up H<sub>2</sub>O Intake Does Not Slow eGFR Decline in CKD
Coaching to Up H2O Intake Does Not Slow eGFR Decline in CKD

WEDNESDAY, May 9, 2018 (HealthDay News) -- Coaching to increase water intake does not significantly slow the decline in kidney function among adults with chronic kidney disease, according to a study published in the May 8 issue of the Journal of the American Medical Association.

William F. Clark, M.D., from the London Health Sciences Centre in Canada, and colleagues conducted a randomized trial involving patients with stage 3 chronic kidney disease and a 24-hour urine volume of less than 3 L. The 316 patients in the hydration group were coached to drink more water, while the 315 in the control group were coached to maintain their usual intake.

The researchers found that among the 590 survivors with one-year follow-up measurements, the hydration group had a mean change in 24-hour urine volume that was 0.6 L per day higher (95 percent confidence interval, 0.5 to 0.7; P < 0.001). The mean change in estimated glomerular filtration rate was −2.2 and −1.9 mL/min/1.73 m² in the hydration and control groups, respectively (adjusted between-group difference, −0.3 mL/min/1.73 m²; 95 percent confidence interval, −1.8 to 1.2; P = 0.74).

"Among adults with chronic kidney disease, coaching to increase water intake compared with coaching to maintain the same water intake did not significantly slow the decline in kidney function after one year," the authors write.

Several authors disclosed ties to Danone Research, which partially funded the study; Thermo Fisher Scientific provided the instrumentation assay reagent and disposables for the analysis.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Cap'n Crunch Cereal Recalled Due to Salmonella Scare

Cap'n Crunch Cereal Recalled Due to <i>Salmonella</i> Scare

No illnesses related to the products have been reported to date

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

FDA Approves First-Line Tx for Peripheral T-Cell Lymphoma

Adcetris approved in combination with chemo to treat systemic anaplastic large cell lymphoma

FDA Warns Against Giving Honey-Filled Pacifiers to Infants

FDA Warns Against Giving Honey-Filled Pacifiers to Infants

Four infants in Texas hospitalized with botulism after using pacifiers containing honey

is free, fast, and customized just for you!




Already a member?

Sign In Now »